BioCentury
ARTICLE | Financial News

Artios launches with $33.2M

September 21, 2016 7:00 AM UTC

Cancer newco Artios Pharma Ltd. (Cambridge, U.K.) raised $33.2 million in a series A round led by SV Life Sciences. Merck Ventures, Imperial Innovations Group plc (LSE:IVO), Arix Bioscience plc, the CRT Pioneer Fund of Cancer Research Technology, and AbbVie Ventures also participated.

Artios is developing therapies targeting DNA damage repair (DDR) pathways. The company in-licensed two assets from CRT, the development and commercialization arm of Cancer Research UK. The preclinical lead program targets DNA-directed DNA polymerase theta (POLQ). Artios and CRT also began a research collaboration to discover and develop additional DDR-targeted molecules. ...